Colistin, an “old” polymyxin antibiotic, is increasingly being used as last-line treatment
against infections caused by multidrug-resistant gram-negative bacteria. It is administered in …

Since their reintroduction into the clinic in the 1980s, the polymyxin antibiotics colistin—
administered intravenously as an inactive prodrug, colistin methanesulfonate (CMS)—and …

Objectives Combination therapy is an important option in the fight against Gram-negative
'superbugs'. This study systematically investigated bacterial killing and the emergence of …

Background The use of fosfomycin for treatment of systemic infections due to MDR
Pseudomonas aeruginosa is increasing. However, pharmacodynamic data for fosfomycin …

Objectives Colistin remains a last-line treatment for MDR Acinetobacter baumannii and
combined use of colistin and carbapenems has shown synergistic effects against MDR …

Objectives Colistin is an 'old'drug, which is being increasingly utilized due to limited
therapeutic options. However, resistance emergence during monotherapy is concerning …

Objectives In the era of emergence of MDR Pseudomonas aeruginosa, osteoarticular
infections (OIs) add more difficulties to its treatment. The role of β-lactams (BLs) is …

Polymyxin combination therapy is increasingly used clinically. However, systematic
investigations of such combinations are a relatively recent phenomenon. The emerging …

Antibiotic combinations are often used for treating Pseudomonas aeruginosa infections but
their efficacy toward intracellular bacteria has not been investigated so far. We have studied …

Background: Because of the rapid spread of antimicrobial resistance and the slow
development of novel antimicrobials, Gram-negative infections treatments are challenging …